Method of obtaining thermostable dried vaccine formulations
View Patent ↗This present invention relates to compositions and methods for stabilizing a dried vaccine formulations. In particular, the invention provides a method for producing a vaccine composition comprising the steps of providing an aqueous composition comprising a buffer, the vaccine components and between 17.5% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, and applying microwave radiation under a pressure lower than atmospheric pressure in order to sublimate the composition and obtain a dried vaccine formulation. The invention also provides a product obtainable by this method.
1. A method for drying a vaccine composition comprising a virus or viral protein subunit or virus-like particles comprising the steps of:
a) providing an aqueous composition in a primary container comprising a buffer, the virus or viral protein subunit or virus-like particles, and between about 20% w/w and about 60% w/w of one or more non-polymeric sugars;
b) freezing the composition, thereby forming at least one frozen body comprising the buffer in frozen form; and
c) applying microwave radiation in a traveling wave format at a power in a range of between 0.5 and 8 KW/hr/Kg to the frozen body under a pressure below atmospheric pressure to produce a dried formulation.
2. The method according to claim 1 , wherein the composition is sublimated in less than 12 hours.
3. The method according to claim 1 , wherein the composition is sublimated in 3 to 8 hours.
4. The method according to claim 1 , wherein the pressure is in the range of 20 to 500 mTorr.
5. The method according to claim 4 , wherein the pressure is in the range of 20 to 200 mTorr.
6. The method according to claim 1 , wherein the temperature of the composition in step c) does not exceed 45° C.
7. The method according to claim 1 , wherein the temperature of the composition in step c) does not exceed 35° C.
8. The method according to claim 1 , wherein the amount of the sugar in the aqueous composition is chosen from the group that consists of the ranges 20-55% w/w, 20-50% w/w, 20-45% w/w, 25-45% w/w, 25-47.5% w/w, 25-40% w/w, 30-47.5% w/w, 30-40% w/w, 25-35% w/w or 27-30% w/w.
9. The method according to claim 1 , characterised in that the sugar comprises monomeric and/or dimeric molecules.
10. The method according to claim 9 , wherein the sugar is glucose, galactose, maltose, sucrose, trehalose, fructose, lactose, saccharose, mannitol, sorbitol, xylitol or a combination thereof.
11. The method according to claim 1 , wherein the vaccine is a combination vaccine.
12. The method according to claim 1 , wherein the vaccine is an enveloped virus vaccine.
13. The method according to claim 1 , wherein the primary container is selected from glass vial, resin vials, plastic vials, dual cartridge device, or foil-pouch based devices vaccine.
14. The method according to claim 1 , wherein the moisture content of the composition after drying is less than 6.0%.
15. The method according to claim 1 , wherein the dried product formed comprises the vaccine dispersed in a solid matrix of a non-polymeric sugar.
16. The method according to claim 1 , wherein the composition is flash frozen.
17. The method according to claim 12 , wherein the enveloped virus is live.
18. The method according to claim 12 , wherein the enveloped virus is selected from cytomegalovirus, herpes simplex virus, measles, mumps, respiratory syncytial virus, rotavirus, rubella, dengue and varicella.
19. The method according to claim 1 , wherein the ratio of power distribution between the first half cycle and total drying power is 15% to 50%.
20. The method according to claim 1 , wherein the ratio of power distribution between the first half cycle and total drying power is 15% to 30%.